A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
Top Cited Papers
- 12 April 2020
- journal article
- research article
- Published by Elsevier BV in Travel Medicine and Infectious Disease
- Vol. 35, 101646
- https://doi.org/10.1016/j.tmaid.2020.101646
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive studyThe Lancet, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, ChinaInternational Journal of Infectious Diseases, 2020
- Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by RemdesivirViruses, 2019
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- ZINC 15 – Ligand Discovery for EveryoneJournal of Chemical Information and Modeling, 2015
- ModBase, a database of annotated comparative protein structure models and associated resourcesNucleic Acids Research, 2013
- Identification of Novel Inhibitors of the SARS Coronavirus Main Protease 3CLproBiochemistry, 2004
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domainThe EMBO Journal, 2002